Resource Logo
Reuters New Media

Some South African clinics running short of HIV/AIDS drugs - MSF




 

Nov 28 (Reuters) - One in five South African clinics are running short of life-saving HIV/AIDS drugs, affecting nearly half a million people and undermining the success of the world's largest treatment programme, medical charities said on Thursday.

With about 6 million people infected with the virus - more than 10 percent of the population - South Africa carries the world's heaviest HIV/AIDS caseload and has around 2.5 million people taking antiretroviral (ARV) drugs daily.

However, the huge numbers are causing the system to creak, health researchers say.

Medical charity Médecins Sans Frontières surveyed more than 2,300 of South Africa's 3,800 public health facilities and found that one in five had either run short or run out of drugs in the previous three months.

Of the affected clinics, catering for 420,000 patients, 20 percent said they had had to turn away patients, putting the effectiveness of the ARV treatment plan at risk, MSF said.

"The sheer scale of the problem shows stock-outs to be one of the principal barriers to maintaining an effective treatment programme," said Anele Yawa of the Treatment Action Campaign, an HIV/AIDS advocacy group that took part in the research.

The health ministry acknowledged some problems but said MSF was exaggerating the situation.

"When you are running a project as big as this, you're likely to have some challenges," said health ministry spokesman Joe Maila. "We accept there's a problem but the level at which they pitched it is an extreme over-exaggeration."

A year ago, South Africa awarded a $667 million two-year contract to pharmaceutical firms including Aspen Pharmacare , Abbott Laboratories and Adcock Ingram to supply HIV/AIDS medication. (Reporting by Tiisetso Motsoeneng; Editing by Ed Cropley)



 


Copyright © 2013 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in November 28, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.